AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
RxSight investors with losses over $75,000 may sue for damages.
ByAinvest
Sunday, Sep 21, 2025 7:25 am ET1min read
Faruqi & Faruqi, a securities law firm, is investigating potential claims against RxSight, Inc. for alleged misrepresentations in the company's financial statements between May 7, 2024 and July 8, 2025. The firm encourages investors who suffered losses exceeding $75,000 to contact Josh Wilson directly to discuss their options. A federal securities class action has been filed against the company, with a September 22, 2025 deadline to seek the role of lead plaintiff.
New York, Sept. 12, 2025 — Leading securities law firm Faruqi & Faruqi, LLP has announced that it is investigating potential claims against RxSight, Inc. (NASDAQ: RXST) for alleged misrepresentations in the company's financial statements between May 7, 2024 and July 8, 2025. The firm encourages investors who suffered losses exceeding $75,000 to contact Josh Wilson directly to discuss their options. A federal securities class action has been filed against the company, with a September 22, 2025 deadline to seek the role of lead plaintiff [1].The complaint alleges that RxSight and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose significant issues. These include adoption challenges and structural problems that led to declines in sales and utilization, overstated demand for the company's products, and an inability to meet previously issued financial guidance for fiscal year 2025 [1].
On July 8, 2025, after the market closed, RxSight reported significant declines in Light Adjustable Lens (LAL) sales, LAL utilization, and overall revenue. The company also lowered its full-year 2025 guidance by approximately $42.5 million at the midpoint. The stock price subsequently fell by $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025 [1].
Investors are reminded that they have until September 22, 2025 to ask the Court to be appointed as lead plaintiff in the case. The lead plaintiff will oversee the litigation on behalf of the class, and any member of the class can choose to remain an absent class member [1].
Faruqi & Faruqi, LLP encourages anyone with information regarding RxSight's conduct to contact the firm, including whistleblowers, former employees, and shareholders. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995 [1].
For more information, investors can visit www.faruqilaw.com/RXST or contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) [1].
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet